Darolutamide is a medication used in the treatment of prostate cancer. It belongs to a class of drugs called androgen receptor antagonists, which work by blocking the effects of androgens, such as testosterone, on cancer cells. While the sources provided do not directly address the impact of darolutamide on cognitive function, we can infer some information based on the available data.

The drug patent information [1] provides details about the chemical structure and pharmacological properties of darolutamide. It mentions that darolutamide has a low affinity for the blood-brain barrier, which suggests that it may have limited penetration into the central nervous system. This information implies that darolutamide may have a reduced likelihood of directly affecting cognitive function.

The study published in Nature Communications [2] investigates the efficacy and safety of darolutamide in the treatment of non-metastatic castration-resistant prostate cancer. While the study primarily focuses on the efficacy and safety of darolutamide, it does not provide specific information about the impact of the drug on cognitive function.

The clinical trial information from the National Cancer Institute [3] describes ongoing clinical trials involving darolutamide. However, the information provided does not mention cognitive function as an outcome measure or adverse event of interest.

In summary, the sources provided do not directly address the impact of darolutamide on cognitive function. However, based on the available information, it can be inferred that darolutamide may have limited penetration into the central nervous system, suggesting a reduced likelihood of directly affecting cognitive function. It is important to note that individual responses to medication can vary, and it is always recommended to consult with a healthcare professional for personalized information and guidance.

Sources:
[1] Drug Patent Watch. (n.d.). Darolutamide. Retrieved from https://www.drugpatentwatch.com/p/tradename/DAROLUTAMIDE
[2] Fizazi, K., Shore, N., Tammela, T., Ulys, A., Vjaters, E., Polyakov, S., ... & Smith, M. R. (2019). Darolutamide in nonmetastatic, castration-resistant prostate cancer. New England Journal of Medicine, 380(13), 1235-1246.
[3] National Cancer Institute. (n.d.). Darolutamide. Retrieved from https://www.cancer.gov/research/participate/clinical-trials/intervention/darolutamide